{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T14:04:25Z","timestamp":1786889065727,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.clml.2018.03.010","type":"journal-article","created":{"date-parts":[[2018,3,31]],"date-time":"2018-03-31T00:07:22Z","timestamp":1522454842000},"page":"431-437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenstr\u00f6m Macroglobulinemia"],"prefix":"10.1016","volume":"18","author":[{"given":"Evangelos","family":"Eleutherakis-Papaiakovou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Christoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Roussou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kanellias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Papatheodorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.03.010_bib1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3324\/haematol.2009.017251","article-title":"Pathophysiology of Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"95","author":"Stone","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.03.010_bib2","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.V82.10.3148.3148","article-title":"Incidence of Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"82","author":"Herrinton","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.010_bib3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/1097-0142(19880915)62:6<1163::AID-CNCR2820620620>3.0.CO;2-6","article-title":"Histologic evidence of an abnormal bone remodeling in B-cell malignancies other than multiple myeloma","volume":"62","author":"Marcelli","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.03.010_bib4","first-page":"287","article-title":"Interleukin 6\/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer","volume":"7","author":"Weidle","year":"2010","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.clml.2018.03.010_bib5","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3324\/haematol.12530","article-title":"The IL6(-174G\/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenstrom macroglobulinemia patients aged 65 years or less","volume":"93","author":"Poulain","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.03.010_bib6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-2141.2003.04561.x","article-title":"Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma","volume":"123","author":"Terpos","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.03.010_bib7","first-page":"6","article-title":"Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma","volume":"11","author":"Spanoudakis","year":"2016","journal-title":"Blood Cancer"},{"key":"10.1016\/j.clml.2018.03.010_bib8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/17474086.2013.874943","article-title":"Management of bone disease in multiple myeloma","volume":"7","author":"Terpos","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2018.03.010_bib9","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.010_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3816\/CLML.2011.n.024","article-title":"Expression of CCL3 by neoplastic cells in patients with Waldenstr\u00f6m\u2019s macroglobulinemia: an immunohistochemical study in bone marrow biopsies of 67 patients","volume":"11","author":"Terpos","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.03.010_bib11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2141.2006.06017.x","article-title":"Abnormal bone remodeling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1\u03b1) in Waldenstr\u00f6m macroglobulinemia","volume":"133","author":"Terpos","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.03.010_bib12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/leu.2015.259","article-title":"Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: role of chemokine (C-C motif) ligand 20","volume":"30","author":"Palma","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.03.010_bib13","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/leu.2009.130","article-title":"Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma","volume":"23","author":"Roussou","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.03.010_bib14","first-page":"6","article-title":"A\u00a0gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival","volume":"16","author":"Botta","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2018.03.010_bib15","doi-asserted-by":"crossref","first-page":"240","DOI":"10.5603\/FHC.2011.0033","article-title":"Proinflammatory chemokine gene expression influences survival of patients with non-Hodgkin\u2019s lymphoma","volume":"49","author":"Mazur","year":"2011","journal-title":"Folia Histochem Cytobiol"},{"key":"10.1016\/j.clml.2018.03.010_bib16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1006\/cyto.1998.0439","article-title":"Abundant expression of chemokines in malignant and infective human lymphadenopathies","volume":"11","author":"Tedla","year":"1999","journal-title":"Cytokine"},{"key":"10.1016\/j.clml.2018.03.010_bib17","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1189\/jlb.72.4.780","article-title":"Role of the autocrine chemokines MIP-1alpha and MIP-1beta in the metastatic behavior of murine T cell lymphoma","volume":"72","author":"Menten","year":"2002","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.clml.2018.03.010_bib18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3109\/10428194.2015.1068308","article-title":"CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates","volume":"57","author":"Hartmann","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.03.010_bib19","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1158\/0008-5472.CAN-08-4173","article-title":"CD38\/CD31, the CCL3 and CCL4 chemokines, and CD49d\/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival","volume":"69","author":"Zucchetto","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2018.03.010_bib20","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood-2010-09-307249","article-title":"CCL3 (MIP-1\u03b1) plasma levels and the risk for disease progression in chronic lymphocytic leukemia","volume":"117","author":"Sivina","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.010_bib21","doi-asserted-by":"crossref","first-page":"78269","DOI":"10.18632\/oncotarget.13412","article-title":"A\u00a0randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia","volume":"7","author":"Kay","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2018.03.010_bib22","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hon.2283","article-title":"Macrophage inflammatory protein 1 alpha (MIP-1\u03b1) may be associated with poor outcome in patients with extranodal NK\/T-cell lymphoma","volume":"35","author":"Kim","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2018.03.010_bib23","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjh.13659","article-title":"CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma","volume":"171","author":"Takahashi","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.03.010_bib24","first-page":"63","article-title":"Role of CCL3 protein (monocyte inflammatory protein-1 alpha) in lymphoid malignancy","volume":"14","author":"Hamed","year":"2007","journal-title":"Egypt J Immunol"},{"key":"10.1016\/j.clml.2018.03.010_bib25","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1182\/blood-2011-04-351742","article-title":"Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity","volume":"118","author":"Elsawa","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.010_bib26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1359-6101(02)00045-X","article-title":"Macrophage inflammatory protein-1","volume":"13","author":"Menten","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.clml.2018.03.010_bib27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/JCO.1995.13.3.575","article-title":"Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma","volume":"13","author":"Seymour","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.010_bib28","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/ijc.27892","article-title":"Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy","volume":"132","author":"Chang","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2018.03.010_bib29","first-page":"110","article-title":"Role of CCL5 and interleukin-6 in the biology of Waldenstr\u00f6m macroglobulinemia","author":"Elsawa","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.010_bib30","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1182\/blood-2007-05-092098","article-title":"The Akt pathway regulates survival and homing in Waldenstr\u00f6m macroglobulinemia","volume":"110","author":"Leleu","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.010_bib31","doi-asserted-by":"crossref","first-page":"51024","DOI":"10.18632\/oncotarget.16882","article-title":"Relevance of CCL3\/CCR5 axis in oral carcinogenesis","volume":"8","author":"da Silva","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2018.03.010_bib32","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1158\/1078-0432.CCR-05-0181","article-title":"Malignant B-Lymphoid cells with bone lesions express receptor activator of nuclear factor-\u03baB ligand and vascular endothelial growth factors to enhance osteoclastogenesis","volume":"11","author":"Shibata","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.03.010_bib33","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/jor.22873","article-title":"Prognostic role of nuclear factor\/IB and bone remodeling proteins in metastatic giant cell tumor of bone: a retrospective study","volume":"33","author":"Quattrini","year":"2015","journal-title":"J\u00a0Orthop Res"},{"key":"10.1016\/j.clml.2018.03.010_bib34","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.18632\/oncotarget.6795","article-title":"Clinical prognostic significance and pro-metastatic activity of RANK\/RANKL via the AKT pathway in endometrial cancer","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2018.03.010_bib35","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/PAT.0000000000000116","article-title":"Impact of RANK signaling on survival and chemotherapy response in osteosarcoma","volume":"46","author":"Bago-Horvath","year":"2014","journal-title":"Pathology"},{"key":"10.1016\/j.clml.2018.03.010_bib36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fimmu.2012.00261","article-title":"Emerging functions of RANKL in lymphoid tissues","volume":"3","author":"Mueller","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2018.03.010_bib37","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jtho.2017.11.121","article-title":"RANKL signaling sustains primary tumor growth in genetically engineered mouse models of lung adenocarcinoma","volume":"13","author":"Faget","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clml.2018.03.010_bib38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","article-title":"Dual effects of macrophage inflammatory protein-1 alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease","volume":"102","author":"Oyajobi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.010_bib39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11010-007-9485-7","article-title":"Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K\/Akt pathways","volume":"304","author":"Tsubaki","year":"2007","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.clml.2018.03.010_bib40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000369975","article-title":"RANK ligand blockade with denosumab in combination with sorafenib in chemorefractory osteosarcoma: a possible step forward?","volume":"88","author":"Cathomas","year":"2015","journal-title":"Oncology"},{"key":"10.1016\/j.clml.2018.03.010_bib41","first-page":"317ra197","article-title":"RANKL blockade prevents and treats aggressive osteosarcomas","volume":"7","author":"Chen","year":"2015","journal-title":"Sci Transl"},{"key":"10.1016\/j.clml.2018.03.010_bib42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ctrv.2017.10.010","article-title":"The anti-tumor effect of RANKL inhibition in malignant solid tumors\u2014a systematic review","volume":"62","author":"de Groot","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clml.2018.03.010_bib43","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.phrs.2015.08.004","article-title":"Therapeutic potential of chemokine signal inhibition for metastatic breast cancer","volume":"100","author":"Kitamura","year":"2015","journal-title":"Pharmacol Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018300892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018300892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:25Z","timestamp":1761870625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018300892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S2152265018300892"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.03.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenstr\u00f6m Macroglobulinemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}